Condition: PSMA Positive Tumors or Tumor Tissues · Prostate Cancer Metastatic · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
This prospective clinical study aims to evaluate the predictive power of PSMA PET imaging in patients with advanced prostate cancer who are receiving systemic drug therapies. The primary goal is to identify prognostic factors derived from PSMA PET imaging. These factors include the number of cancer lesions, the size of the tumor, and measurements known as SUVmax and SUVmean. By identifying these factors, the investigators aim to better group patients and predict those who may have a less favorable outcome. While PSMA PET imaging is highly accurate in locating cancer sites within the body, its ability to predict treatment response has not yet been thoroughly studied in a prospective manner for this patient population. This study will assess the predictive role of PSMA PET imaging and its ability to forecast treatment response across a range of systemic therapies, including hormone therapy and chemotherapy, in patients with both hormone-sensitive (HSPC) and castration-resistant (CRPC) prostate cancer.
This description comes directly from the study's public registry record.
Andrea Farolfi, MD · +390512143959 · andrea.farolfi@aosp.bo.it
Andrea Di Giorgio, MD · +390512143959 · andrea.digiorgio@live.it
Always discuss trial participation with your own doctor first.
| Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna | Bologna, Italy, Italy | Recruiting |
| Azienda Ospedaliera Santa Croce e Carle - ospedale Santa Croce | Cuneo, Italy, Italy | Recruiting |
| U.O. Medicina Nucleare, IRCCS Ospedale Policlinico San Martino | Genova, Italy, Italy | Recruiting |
| UOC Medicina Nucleare, AOU Policlinico G.Martino | Messina, Italy, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07089550